CD274 and non-small cell lung carcinoma: In the initial setting, pembrolizumab monotherapy has shown improvements in progression-free survival (PFS) and overall survival (OS) benefits compared to chemotherapy in NSCLC patients with PD-L1 expression on \documentclass[12pt]{minimal}\usepackage{amsmath}\usepackage{wasysym}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{amsbsy}\usepackage{mathrsfs}\usepackage{upgreek}\setlength{\oddsidemargin}{-69pt}\begin{document}$$\ge 50\%$$\end{document}≥50% of tumor cells11,12.